Evidence map›Paper›PMID 41324163›Full record

ArticleThe Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology2026

Drug repositioning of regorafenib for renal cell carcinoma identifies

Jihwan Moon, Vu T A Vo, Le Tran Nhat, Minseob Eom, Yangsik Jeong

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. What KJPP looks for: guidance from initial editorial screening.The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jihwan MoonDepartment of Pathology, Yonsei University Wonju College of Medicine, Wonju 26426, Korea.
Vu T A VoDepartment of Biochemistry, Yonsei University Wonju College of Medicine, Wonju 26426, Korea.
Le Tran NhatDepartment of Biochemistry, Yonsei University Wonju College of Medicine, Wonju 26426, Korea.
Minseob EomDepartment of Pathology, Yonsei University Wonju College of Medicine, Wonju 26426, Korea.
Yangsik JeongDepartment of Biochemistry, Yonsei University Wonju College of Medicine, Wonju 26426, Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Renal cell carcinoma (RCC) is heterogeneous and frequently refractory to cytotoxic therapy. We investigated whether contexts with elevated DDR2-a collagenactivated receptor tyrosine kinase-are preferentially sensitive to regorafenib, a multikinase inhibitor with activity against DDR2.

Indexed as

Discoidin domain receptor 2Drug repositioningExtracellular matrixRenal cell carcinomaTyrosine kinase inhibitors

Identifiers

PMID41324163
PMCPMC12723414

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.